VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

NCT00564161 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-09-02

No results posted yet for this study

Summary

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Conditions

  • Preterm Infants With White Matter Damage
  • Preterm Infants Developing Normally

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Talya Dor, MD · Hadassah Medical Organization

Eligibility

Min Age
25 Weeks
Max Age
40 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Completion
2009-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564161 on ClinicalTrials.gov